Novo Nordisk A S annual current ratio
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Current Ratio Growth & History (NVO)
Novo Nordisk A S's current ratio was 0.80 for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.80 | 0.06 | +7.56% |
| 2024 | 2024-12-31 | 0.74 | −0.08 | −9.68% |
| 2023 | 2023-12-31 | 0.82 | −0.07 | −7.99% |
| 2022 | 2022-12-31 | 0.89 | 0.03 | +4.01% |
| 2021 | 2021-12-31 | 0.86 | −0.08 | −8.15% |
| 2020 | 2020-12-31 | 0.94 | −0.12 | −11.56% |
| 2019 | 2019-12-31 | 1.06 | — | — |
Novo Nordisk A S quarterly current ratio
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.87 | 0.09 | +11.33% |
| Q1 2026 | 2026-03-31 | 0.79 | — | — |
| Q4 2025 | 2025-12-31 | 0.80 | 0.06 | +7.56% |
| Q3 2025 | 2025-09-30 | 0.78 | — | — |
| Q2 2025 | 2025-06-30 | 0.78 | — | — |
| Q4 2024 | 2024-12-31 | 0.74 | −0.08 | −9.68% |
| Q4 2023 | 2023-12-31 | 0.82 | −0.07 | −7.99% |
| Q4 2022 | 2022-12-31 | 0.89 | 0.03 | +4.01% |
| Q4 2021 | 2021-12-31 | 0.86 | −0.08 | −8.15% |
| Q4 2020 | 2020-12-31 | 0.94 | — | — |
Novo Nordisk A S current ratio trends
Over the last five fiscal years, Novo Nordisk A S's current ratio decreased from 0.94 to 0.80, a change of −0.14. The latest reported quarter, Q2 2026, shows 0.87.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...